These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

571 related items for PubMed ID: 17295600

  • 1. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride.
    Issa MM, Runken MC, Grogg AL, Shah MB.
    Am J Manag Care; 2007 Feb; 13 Suppl 1():S10-6. PubMed ID: 17295600
    [Abstract] [Full Text] [Related]

  • 2. Finasteride versus dutasteride: a real-world economic evaluation.
    Fenter TC, Runken MC, Black L, Eaddy M.
    Am J Manag Care; 2007 Feb; 13 Suppl 1():S23-8. PubMed ID: 17295602
    [Abstract] [Full Text] [Related]

  • 3. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years.
    Fenter TC, Davis EA, Shah MB, Lin PJ.
    Am J Manag Care; 2008 May; 14(5 Suppl 2):S154-9. PubMed ID: 18611089
    [Abstract] [Full Text] [Related]

  • 4. Differences in alpha blocker usage among enlarged prostate patients receiving combination therapy with 5 ARIs.
    Naslund M, Black L, Eaddy M, Batiste LR.
    Am J Manag Care; 2007 Feb; 13 Suppl 1():S17-22. PubMed ID: 17295601
    [Abstract] [Full Text] [Related]

  • 5. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
    Naslund M, Eaddy MT, Hogue SL, Kruep EJ, Shah MB.
    Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
    [Abstract] [Full Text] [Related]

  • 6. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ, Miner M.
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [Abstract] [Full Text] [Related]

  • 7. Clinical and economic outcomes in patients treated for enlarged prostate.
    Naslund MJ, Issa MM, Grogg AL, Eaddy MT, Black L.
    Am J Manag Care; 2006 Mar; 12(4 Suppl):S111-6. PubMed ID: 16551204
    [Abstract] [Full Text] [Related]

  • 8. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG, Barkin J, Siami P, Tubaro A, Wilson TH, Morrill BB, Gagnier RP.
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [Abstract] [Full Text] [Related]

  • 9. 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery.
    Boyle P, Roehrborn C, Harkaway R, Logie J, de la Rosette J, Emberton M.
    Eur Urol; 2004 May; 45(5):620-6; discussion 626-7. PubMed ID: 15082205
    [Abstract] [Full Text] [Related]

  • 10. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design.
    Siami P, Roehrborn CG, Barkin J, Damiao R, Wyczolkowski M, Duggan A, Major-Walker K, Morrill BB, CombAT study group.
    Contemp Clin Trials; 2007 Nov; 28(6):770-9. PubMed ID: 17761460
    [Abstract] [Full Text] [Related]

  • 11. Cost comparison of finasteride and dutasteride for enlarged prostate in a managed care setting among Medicare-aged men.
    Naslund M, Eaddy MT, Kruep EJ, Hogue SL.
    Am J Manag Care; 2008 May; 14(5 Suppl 2):S167-71. PubMed ID: 18611091
    [Abstract] [Full Text] [Related]

  • 12. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
    Kuiper JG, Bezemer ID, Driessen MT, Vasylyev A, Roehrborn CG, Penning-van Beest FJ, Herings RM.
    BMC Urol; 2016 Aug 31; 16(1):53. PubMed ID: 27580700
    [Abstract] [Full Text] [Related]

  • 13. Comparative analysis of alpha-blocker utilization in combination with 5-alpha reductase inhibitors for enlarged prostate in a managed care setting among Medicare-aged men.
    Issa MM, Lin PJ, Eaddy MT, Shah MB, Davis EA.
    Am J Manag Care; 2008 May 31; 14(5 Suppl 2):S160-6. PubMed ID: 18611090
    [Abstract] [Full Text] [Related]

  • 14. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.
    Roehrborn CG, Bruskewitz R, Nickel JC, McConnell JD, Saltzman B, Gittelman MC, Malek GH, Gottesman JE, Suryawanshi S, Drisko J, Meehan A, Waldstreicher J, Proscar Long-Term Efficacy and Safety Study Group.
    J Urol; 2004 Mar 31; 171(3):1194-8. PubMed ID: 14767299
    [Abstract] [Full Text] [Related]

  • 15. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
    Roehrborn CG, Nickel JC, Andriole GL, Gagnier RP, Black L, Wilson TH, Rittmaster RS.
    Urology; 2011 Sep 31; 78(3):641-6. PubMed ID: 21764428
    [Abstract] [Full Text] [Related]

  • 16. 5-Alpha reductase inhibitors in men with an enlarged prostate: an evaluation of outcomes and therapeutic alternatives.
    Naslund M, Regan TS, Ong C, Hogue SL.
    Am J Manag Care; 2008 May 31; 14(5 Suppl 2):S148-53. PubMed ID: 18611088
    [Abstract] [Full Text] [Related]

  • 17. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
    Montorsi F, Alcaraz A, Desgrandchamps F, Hammerer P, Schröder F, Castro R.
    Prostate; 2009 Jun 01; 69(8):895-907. PubMed ID: 19267353
    [Abstract] [Full Text] [Related]

  • 18. Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia.
    Dolder CR.
    Ann Pharmacother; 2006 Apr 01; 40(4):658-65. PubMed ID: 16569804
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
    Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C, ARIA3001, ARIA3002 and ARIB3003 Study Investigators.
    Eur Urol; 2004 Oct 01; 46(4):488-94; discussion 495. PubMed ID: 15363566
    [Abstract] [Full Text] [Related]

  • 20. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002).
    Vela-Navarrete R, Gonzalez-Enguita C, Garcia-Cardoso JV, Manzarbeitia F, Sarasa-Corral JL, Granizo JJ.
    BJU Int; 2005 Nov 01; 96(7):1045-8. PubMed ID: 16225526
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.